In the STEMI with MetS group, the prevalence of MACCE was markedly higher in patients with high-MIF levels (76.9%) than those with low-MIF levels (18.7%) at the end of a 4.9-year follow-up period (Figure 4B, P < 0.001). The gene discussed is MIF; the disease is metabolic syndrome.